XML 17 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 6 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2020
Total revenue $ 299.8 $ 678.4 $ 690.6 $ 638.6
Costs and expenses:        
Research and development expense 35.8 85.4 81.9 77.2
Selling, general, and administrative expense 260.4 514.7 537.8 507.3
Legal charges pending settlement 0.0 0.0 62.0 0.0
Goodwill and long-lived asset impairment charges 0.0 16.9 1.8 99.7
Total costs and expenses 387.6 819.0 881.1 870.3
Operating loss (87.8) (140.6) (190.5) (231.7)
Other income (expense):        
Interest income 0.7 2.6 0.7 3.0
Interest expense (5.8) (3.2) (6.6) (10.8)
Other (1.2) 0.6 139.3 16.2
Total other income (expense) (6.3) 0.0 133.4 8.4
Loss before income tax (94.1) (140.6) (57.1) (223.3)
Income tax benefit (41.0) (28.6) (29.9) (23.7)
Net loss (53.1) (112.0) (27.2) (199.6)
Net loss attributable to non-controlling interest 0.0 0.0 0.0 (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders $ (53.1) $ (112.0) $ (27.2) $ (199.5)
Net loss per share:        
Basic (in dollars per share) $ (0.71) $ (1.39) $ (0.35) $ (2.69)
Diluted (in dollars per share) $ (0.71) $ (1.39) $ (0.35) $ (2.69)
Weighted average shares outstanding:        
Basic (in shares) 75.0 80.6 78.0 74.3
Diluted (in shares) 75.0 80.6 78.0 74.3
Testing revenue        
Total revenue $ 279.6 $ 678.4 $ 666.4 $ 586.9
Costs and expenses:        
Costs and expenses 82.6 202.0 185.7 157.5
Other revenue        
Total revenue 20.2 0.0 24.2 51.7
Costs and expenses:        
Costs and expenses $ 8.8 $ 0.0 $ 11.9 $ 28.6